ArticleFrontiers in immunology2025
Establishment and validation of survival nomogram score staging for esophageal squamous cell carcinoma patients after minimally invasive surgery combined with immune prognostic index and clinicopathological features.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Minimally invasive esophagectomy (MIE) is commonly applied in the treatment of esophageal squamous cell carcinoma (ESCC). The preoperative immune prognostic index (IPI) is considered a potential indicator for ESCC. In this study, we attempted to establish and validate a comprehensive clinical risk staging toward predicting the long-term outcome in ESCC patients after MIE through the combined application of IPI and clinicopathological features based on nomogram. Methods: Patients diagnosed with ESCC and who were treated with MIE at our center were randomly assigned in a 7:3 ratio to two cohorts: training (n=425) and validation (n=188). Nomograms were then established according to the Cox multivariate results for the training cohort. To evaluate the predictive value and the clinical benefit rate of the nomogram, we employed the calibration curve, decision curve analysis (DCA), and time-dependent area under the curve (t-AUC). The best cut-off value obtained was applied to develop the survival nomogram-scoring (SNS) staging. Results: Patients with ESCC and who underwent MIE exhibited the worse overall survival (OS) and disease-free survival (DFS) with an IPI=2 relative to IPI=0 or 1 (all P < 0.001) in the training and validation cohorts, respectively. According to the multivariate Cox analysis, we established nomograms that combined IPI with the clinicopathological features to predict the OS and DFS. The t-AUC and DCA demonstrated that the nomograms had a better predictive value and clinical benefit rate than the American Joint Committee on Cancer (AJCC) staging. Accordingly, we developed the SNS staging and found that the OS and DFS were significantly different among patients at different stages (all P < 0.001). The dynamic mortality risk rate revealed a double peak in the high-risk patients (12 and 48 months) and a single peak in the low-risk patients (24 months) and middle-risk patients (12 months), which gradually decreased over time. Conclusion: The SNS staging based on IPI and clinicopathological features can thus be applied to effectively evaluate the OS and DFS of ESCC patients after MIE. Our findings may facilitate the development of clinical follow-up strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.